title: Feasibility and efficacy of dose-dense and dose-intense ABVD for high-risk patients with advanced Hodgkin lymphoma: reply to D'Arco et al.
authors.affiliation: Haematology-Oncology and Stem Cell Transplantation Unit, Department of Haematology, National Cancer Institute, Fondazione 'G. Pascale', IRCCS, Naples, Italy. apinto.int.napoli@tin.it, a.pinto@istitutotumori.na.it.
authors.forename: Antonello
authors.initials: A
authors.lastname: Pinto
authors.affiliation: Haematology-Oncology and Stem Cell Transplantation Unit, Department of Haematology, National Cancer Institute, Fondazione 'G. Pascale', IRCCS, Naples, Italy.
authors.forename: Gaetano
authors.initials: G
authors.lastname: Corazzelli
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D003606:Dacarbazine / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D014747:Vinblastine / Q000008:administration & dosage
chemical_list: D001761:Bleomycin; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin
keywords: ABVD; Hodgkin lymphoma; dose intensity; doxorubicin; interim positron emission tomography